Phase 2 biotech developing therapies for cirrhosis.
Industry: Health Care
First Day Return: -0.1%
Industry: Health Care
IPO Data | |
---|---|
IPO File Date | 04/30/2019 |
Offer Price | $10.00 |
Price Range n/a | |
Offer Shares (mm) | 1.6 |
Deal Size ($mm) | $16 |
Lock-Up Date | IPO Pro Only |
Street Research | IPO Pro Only |
IPO Data | |
---|---|
IPO Date | 09/17/2020 |
Offer Price | IPO Intelligence Only |
Price Range | IPO Intelligence Only |
Offer Shares (mm) | IPO Intelligence Only |
Deal Size ($mm) | $16 |
Lock-Up Date | IPO Intelligence Only |
Street Research | IPO Intelligence Only |
Underwriters |
---|
IPO Intelligence Only |
Company Data | |
---|---|
Headquarters | Los Angeles, CA, United States |
Founded | 2013 |
Employees at IPO | 5 |
Website www.biovieinc.com |